Trial Profile
A study of nivolumab and pembrolizumab in patients with uveal-melanoma and mucosal melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2016
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma; Uveal melanoma
- Focus Therapeutic Use
- 25 Jul 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology